These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31400155)

  • 1. Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
    Cristelli MP; Felipe CR; Prizmic PSS; de Azevedo VFD; Viana LA; Tavares MG; Wagner de Castro Lima Santos D; de Paula MI; Medina-Pestana JO; Tedesco-Silva Junior H
    Clin Transplant; 2019 Oct; 33(10):e13689. PubMed ID: 31400155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy.
    Felipe C; Ferreira AN; de Paula M; Viana L; Cristelli M; Medina Pestana J; Tedesco-Silva H
    Transpl Infect Dis; 2019 Dec; 21(6):e13106. PubMed ID: 31081566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of mTOR inhibitors on the incidence of CMV infection in high-risk donor positive-recipient negative (D+/R-) kidney transplant recipients.
    Cristelli MP; Esmeraldo RM; Pinto CM; Sandes-Freitas TV; Felipe C; Lobo CF; Viana L; Mansur J; Stopa S; Santos DWC; Grenzi PC; Aguiar WF; Tedesco-Silva H; Pestana JOM
    Transpl Infect Dis; 2018 Aug; 20(4):e12907. PubMed ID: 29679515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of anti-thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis.
    Basso G; Felipe CR; Cristelli MP; Mansur Siliano J; Viana L; Ferreira Brigido AN; Stopa Martins SB; de Castro Lima Santos DW; Aguiar WF; Tedesco-Silva Junior H; Medina-Pestana JO
    Transpl Infect Dis; 2018 Aug; 20(4):e12919. PubMed ID: 29797676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
    Ferreira AN; Felipe CR; Cristelli M; Viana L; Mansur J; de Paula M; Wagner D; de Marco R; Gerbase-DeLima M; Proença H; Aguiar W; Medina-Pestana J; Tedesco-Silva Junior H
    Transpl Int; 2019 Nov; 32(11):1127-1143. PubMed ID: 31278785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Tedesco-Silva H; Felipe C; Ferreira A; Cristelli M; Oliveira N; Sandes-Freitas T; Aguiar W; Campos E; Gerbase-DeLima M; Franco M; Medina-Pestana J
    Am J Transplant; 2015 Oct; 15(10):2655-64. PubMed ID: 25988935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.
    Radtke J; Dietze N; Spetzler VN; Fischer L; Achilles EG; Li J; Scheidat S; Thaiss F; Nashan B; Koch M
    Transpl Infect Dis; 2016 Feb; 18(1):79-88. PubMed ID: 26707694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of cytomegalovirus in cardiac transplant recipients receiving induction immunosuppression with antithymocyte globulin.
    Jewani PK; Pouch SM; Kissling KT
    Clin Transplant; 2018 Nov; 32(11):e13420. PubMed ID: 30290013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis.
    Manière L; Noble J; Terrec F; Bennani HN; Chevallier E; Janbon B; Germi R; Bugnazet M; Imerzoukene F; Malvezzi P; Rostaing L; Jouve T
    Int Urol Nephrol; 2021 Mar; 53(3):591-600. PubMed ID: 33058036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
    Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
    Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of everolimus in reducing cytomegalovirus events in kidney transplant recipients on steroid-avoidance strategy: 3-year follow-up of a randomized clinical trial.
    de Sandes-Freitas TV; Pinheiro PMA; Sales MLMBO; Girão CM; Campos ÉF; Esmeraldo RM
    Transpl Int; 2018 Dec; 31(12):1345-1356. PubMed ID: 29969826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.
    Mallat SG; Tanios BY; Itani HS; Lotfi T; McMullan C; Gabardi S; Akl EA; Azzi JR
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1321-1336. PubMed ID: 28576905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients.
    Hasegawa J; Hatakeyama S; Wakai S; Omoto K; Okumi M; Tanabe K; Mieno M; Shirakawa H
    Int J Infect Dis; 2017 Dec; 65():50-56. PubMed ID: 28986314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic CMV therapy does not improve three-yr patient and graft survival compared to preemptive therapy.
    Werzowa J; Schwaiger B; Hecking M; Strassl R; Schmaldienst S; Böhmig GA; Genser B; Säemann MD
    Clin Transplant; 2015 Dec; 29(12):1230-8. PubMed ID: 26458731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone with ganciclovir prophylaxis.
    Lo A; Stratta RJ; Egidi MF; Shokouh-Amiri MH; Grewal HP; Kisilisik AT; Trofe J; Alloway RR; Gaber LW; Gaber AO
    Transpl Infect Dis; 2001 Mar; 3(1):8-15. PubMed ID: 11429034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction.
    Couzi L; Helou S; Bachelet T; Martin S; Moreau K; Morel D; Lafon ME; Garrigue I; Merville P
    Transplant Proc; 2012 Nov; 44(9):2809-13. PubMed ID: 23146529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
    Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
    Trials; 2015 Mar; 16():118. PubMed ID: 25873064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of CMV disease with steroid-free immunosuppresssion in simultaneous pancreas-kidney transplant recipients.
    Axelrod D; Leventhal JR; Gallon LG; Parker MA; Kaufman DB
    Am J Transplant; 2005 Jun; 5(6):1423-9. PubMed ID: 15888050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
    Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
    Miranda TA; Felipe CR; Santos RHN; Medina Pestana JO; Tedesco-Silva Junior H
    Ther Drug Monit; 2020 Dec; 42(6):811-820. PubMed ID: 32657909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.